Experimental Hematology
Volume 37, Issue 9 , Pages 1007-1015 , September 2009

Erythropoietin and erythropoiesis

  • Walter Fried

      Affiliations

    • Corresponding Author InformationOffprint requests to: Walter Fried, M.D., Oncology Specialists, 1700 Luther Lane, Park Ridge, IL 60068

Received 20 April 2009 ,Revised 20 May 2009 ,Accepted 22 May 2009.

References 

  1. Bert P. Sur la richesse en hemoglobine du sang de animaux vivant sur les hauts. C R Acad Sci. 1882;94:805–806
  2. Carnot P, DeFlandre C. Sur l ‘activite’ hematopoietique des differents organs au cours de la regeneration du sang. C R Acad Sci. 1906;143:432–434
  3. Grant WC, Root WS. Fundamental stimulus for erythropoiesis. Physiol Rev. 1952;32:449–498
  4. Reissman KR. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood. 1950;5:372–380
  5. Erslev AJ. Humoral regulation of red cell production. Blood. 1953;8:349–357
  6. Plzak LF, Fried W, Jacobson LO, Bethard WJ. Demonstration of stimulation of erythropoiesis by plasma from anemic rats, using Fe59. J Lab Clin Med. 1955;46:671–678
  7. Fried W, Plzak LF, Jacobson LO, Goldwasser E. Assay of erythropoietin in hypophysectomized rats. Proc Soc Exp Biol Med. 1956;92:203–207
  8. Degowin RL, Hofstra D, Gurney CW. The mouse with hypoxia induced erythremia, an erythropoietin assay animal. J Lab Clin Med. 1962;60:846–852
  9. Goldwasser E, Jacobson LO, Fried W, Plzak LF. Mechanism of the erythropoietic effect of cobalt. Science. 1957;125:1085–1086
  10. Fried W, Gurney CW. Erythropoietic effect of the plasma from mice receiving testosterone. Nature. 1965;206:1160–1161
  11. Stohlman F, Rath E, Ross JC. Evidence of a humoral regulation of erythropoiesis: Studies on a patient with polycythemia secondary to regional hypoxia. Blood. 1954;9:721–733
  12. Jacobson LO, Goldwasser E, Fried W, Plzak LF. Role of the kidney in erythropoiesis. Nature. 1957;139:633–634
  13. Miyake T, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977;252:5558–5564
  14. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985;82:7580–7584
  15. Krantz SB, Goldwasser E. Specific binding of erythropoietin in spleen cells infected with the anemia strain of Fried virus. Proc Natl Acad Sci U S A. 1984;81:7574–7578
  16. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood. 1991;15:2583–2590
  17. McCaffrey PJ, Fraser JK, Lin FK, Berridge MV. Subunit structure of the erythropoietin receptor. J Biol Chem. 1989;264:10507–10512
  18. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following EPO stimulation. Cell. 1993;74:227–236
  19. Miura O, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN, Aoki N. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vitro. Blood. 1994;84:1501–1507
  20. Kilbridge T, Fried W. Response of mice with decreased number of hematopoietic stem cells to doses of erythropoietin. J Lab Clin Med. 1968;72:85–92
  21. Stein RS. The role of erythropoietin in the anemia of myelodysplastic syndrome. Clin Lymphoma. 2005;6:52–55
  22. Fisher JW, Koury S, Ducey T, Mendel S. Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol. 1996;95:27–36
  23. Koury ST, Bondurant MC, Semenza GL, Koury MJ. The use of in situ hybridization to study erythropoietin gene expression in murine kidney and liver. Microsc Res Tech. 1993;39:25–29
  24. Zanjani ED, Ascensao JL, McGlave PM, Banisadre M, Ash RC. Studies on the liver to kidney switch of erythropoietin production. J Clin Invest. 1981;67:1183–1188
  25. Fried W. The liver as a source of extrarenal erythropoietin production. Blood. 1972;40:671–677
  26. Fried W, Barone J, Schade S, Anagnostou A. Effect of carbon tetrachloride on extrarenal erythropoietin production. J Lab Clin Med. 1979;93:700–705
  27. Simon P, Meyrier A, Tanqueerel T, Ang KS. Improvement of anemia in hemodialysed patients after viral or toxic hepatic cytolysis. Br Med J. 1980;280:892–894
  28. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM. Expression of erythropoietin by the human placenta. FASEB J. 1996;10:760–768
  29. Zhang F, Laneville P, Gagnon RF, Morin B, Brox AG. Effect of chronic renal failure on the expression of erythropoietin message in a murine model. Exp Hematol. 1996;24:1469–1474
  30. Burk JR, Lertora JJ, Martinez IR, Fisher JW. Renal cell carcinoma with erythrocytosis and elevated erythropoietic stimulatory activity. South Med J. 1977;70:955–958
  31. Scott D, Theologides A. Hepatoma, erythrocytosis, and increased serum erythropoietin developing in long-standing hemochromatosis. Am J Gastroenterol. 1974;61:206–211
  32. Suzuki M, Takamizawa S, Nomaguchi K, et al. Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis. Br J Haematol. 2001;113:49–51
  33. Matsuo M, Koga S, Kanetake H, et al. EPO-producing gastric carcinoma in a hemodialysis patient. Am J Kidney Dis. 2003;42:E3–E4
  34. Fried W, Plzak LF, Jacobson LO, Goldwasser E. Studies on erythropoiesis III. Factors controlling erythropoietin production. Proc Soc Exp Biol Med. 1957;94:241–243
  35. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science. 1988;242:1412–1415
  36. Wang GL, Semenza GL. General involvement of hypoxia inducible factor in transcriptional response to hypoxia. Proc Soc Natl Acad Sci U S A. 1993;90:4304–4308
  37. Huang LE, Ho V, Kraine D. Erythropoietin gene regulation depends on heme dependant oxygen sensing and assembly of interacting transcription factors. Kidney Int. 1997;51:548–522
  38. Kickler TS, Spivak JL. Repeated blood donations and erythropoietin levels. JAMA. 1989;261:1443–1444
  39. Mirand EA, Gordon AS, Wenig J. Mechanism of testosterone action on erythropoiesis. Nature. 1965;206:270–272
  40. Alexanian R, Vaugh WH, Ruchelman MW. Erythropoietin excretion in man following androgens. J Lab Clin Med. 1967;70:777–785
  41. Doane B, Fried W, Schwartz F. Response of uremic patients to Nandrolone Decanoate. Arch Intern Med. 1975;135:972–975
  42. Jelkmann WE, Fandrey J, Frede S, Pagel H. Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. Ann N Y Acad Sci. 1994;718:300–309
  43. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci. 1994;307:353–354
  44. Kilbridge T, Fried W, Heller P. The mechanism by which plethora suppresses erythropoiesis. Blood. 1969;33:104–113
  45. Necas E, Neuwirt J. Feedback regulation by red cell mass of the sensitivity of the erythropoietin producing organ to hypoxia. Blood. 1970;36:754–763
  46. Fried W, Heller P, Johnson C. Observations on regulation of erythropoiesis during periods of prolonged hypoxia. Blood. 1970;36:607–616
  47. Stohlman F, Brecher G. Humoral regulation of erythropoiesis V. Relationship of plasma erythropoietin activity to bone marrow activity. Proc Soc Exp Biol Med. 1959;100:40–43
  48. Fried W, Barone-Varelas J. Regulation of the plasma erythropoietin level in hypoxic rats. Exp Hematol. 1984;12:706–711
  49. Fried W, Knospe WH, Trobaugh FE. Regulation of plasma erythropoietin levels in mice with impaired response to erythropoietin. J Lab Clin Med. 1971;78:48–56
  50. Naets JP, Wittek M. Effect of erythroid hyperplasia on utilization of erythropoietin. Nature. 1965;206:736–728
  51. Beguin Y, Baron F, Fillet G. Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous stem cell transplant. Haematologia. 1998;83:1076–1081
  52. Cazzola M, Guarnone R, Cerani P, Rovati A, Beguin Y. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood. 1998;91:239–241
  53. de Klerk G, Rosengarten PC, Vet RJ, Goudsmit R. Serum erythropoietin titers in anemia. Blood. 1981;58:1164–1170
  54. Hammond DA, Ishikawa A, Keighly G. The relationship between erythropoietin and severity of anemia in hypoplastic and hemolytic states. In:  Jacobson LO,  Doyle M editor. Erythropoiesis. New York: Grune and Stratton Inc; 1962;p. 351–358
  55. Finne PH. On the correspondence between red cell production and plasma erythropoietin level. Scand J Clin Lab Invest. 1965;17:135–141
  56. Morgan EH, Oates PS. Mechanisms and regulation of intestinal iron absorption. Blood Cells Mol Dis. 2002;29:384–399
  57. Mims MO, Prchal JT. Divalent metal transporter 1. Hematology. 2005;10:339–345
  58. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275:19906–19912
  59. Donovan A, Lima CA, Pincus JL, et al. The iron exporter ferroportin/Sic40a1 is essential for iron homeostasis. Cell Metab. 2005;1:191–200
  60. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide, synthesized in the liver. J Biol Chem. 2001;276:7806–7810
  61. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093
  62. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews C, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117:1933–1939
  63. Ganz T. Molecular control of iron transport. J Am Soc Nephrol. 2007;18:394–400
  64. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoiesis. Blood. 2006;108:3730–3735
  65. Gardeghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in (beta) thalassemia is characterized by increased iron absorption mediated by-down regulation of hepcidin and up-regulation of ferroportin. Blood. 2007;109:5027–5035
  66. Pinto JP, Ribeiro S, Pontes H, et al. Erythropoietin mediates hepcidin expression in hepatocytes through OPOR signaling and regulation of C/EBPalpha. Blood. 2008;111:5727–5733
  67. Peyssonnaux C, Zinkernage AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007;117:1926–1932
  68. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–1101
  69. Wrighting DM, Andrews NC. Interleulin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204–3209
  70. Schade SG, Fried W. The utilization of senescent re cell and hemolysate iron for erythropoiesis. Proc Soc Exp Biol Med. 1976;151:78–83
  71. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end stage renal failure with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73–78
  72. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end stage renal disease. Ann Intern Med. 1989;111:992–1000
  73. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta thalassemia. Haematologica. 2007;92:583–588
  74. Cazzola M, Malcovati L. Myelodysplastic syndromes—coping with ineffective erythropoiesis. N Engl J Med. 2005;352:536–538
  75. Gurney CW, Goldwasser E, Pan C. Studies on erythropoiesis. IV. Erythropoietin in human plasma. J Lab Clin Med. 1957;50:534–540
  76. Gallagher NI, McCarthy JM, Hart KT, Lange RD. Evaluation of plasma erythropoietic stimulating factor in anemic uremic patients. Blood. 1959;14:662–667
  77. Cotes PM, Dor'e CL, Liu Yin JA, et al. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med. 1986;315:283–287
  78. Ward HP, Kurnick JE, Pisarczyk MJ. Serum erythropoietin in anemias associated with chronic infection, malignancy, and primary hematopoietic disease. J Clin Invest. 1971;50:332–335
  79. Erslev AJ, Wilson J, Caro J. Erythropoietin in anemic non-uremic patients. J Lab Clin Med. 1987;109:429–433
  80. Jelkmann W, Weidmann G. Serum erythropoietin level: relationship to blood hemoglobin concentration and erythrocytic activity of the bone marrow. J Mol Biol. 1990;68:403–407
  81. Berlin NI, Wasserman LR. Polycythemia vera: a retrospective and reprise. J Lab Clin Med. 1997;130:366–372
  82. James C, Ugo V, LeCouedic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature. 2005;434:1144–1147
  83. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–1096
  84. Winearls GC, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet. 1986;2:1175–1178
  85. Means RT. Erythropoietin in the treatment of anemia in chronic infectious, inflammatory and malignant diseases. Curr Opin Hematol. 1995;2:210–213
  86. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoietin and darbepoietin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008;111:25–41
  87. Mittleman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol. 1997;98:204–210
  88. Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V. An assessment of erythroid response to epoeitin alpha as a single agent versus in combination with granulocyte or granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer. 2009;15:706–715
  89. Casadevail N, Duroeux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte-colony−stimulating-factor for the treatment of myelodysplastic syndromes: a randomized, controlled trail. Blood. 2004;104:321–327
  90. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and Zidovudine therapy. Ann Intern Med. 1992;117:739–748
  91. Goodnough LT, Price KD, Friedman M, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion. 1994;34:66–71
  92. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  93. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoietin alfa in mainly nonanemic patients with metastatic breast cancer receiving first line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960–5972
  94. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbopoietin administration for the treatment of cancer associated anemia. JAMA. 2008;299:914–924
  95. Fandry J. Erythropoietin receptors on tumor cells: what do they mean. Oncologist. 2008;13(Suppl 3):16–20
  96. Ribatti D, Marzulla A, Gentile A, et al. erythropoietin/erythropoietin receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology. 2007;50:591–596

PII: S0301-472X(09)00180-5

doi: 10.1016/j.exphem.2009.05.010

Experimental Hematology
Volume 37, Issue 9 , Pages 1007-1015 , September 2009

Article Tools